Skip to search formSkip to main contentSkip to account menu

PAD Regimen

Known as: Velcade/Adriamycin/Dexamethasone Regimen, Bortezomib/Doxorubicin/Dexamethasone Regimen, PAD 
A chemotherapy regimen containing bortezomib, doxorubicin and dexamethasone regimen used in the treatment of multiple myeloma.
National Institutes of Health

Related topics

Related topics

3 relations
DexamethasoneDoxorubicinbortezomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement
Dear Editor, Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Although the introduction of proteasome inhibitor… 
2012
2012
Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)
Abstract 5032 Introduction. Combining bortezomib with pegylated liposomal doxorubicin for the treatment of Multiple Myeloma (MM… 
2012
2012
Fulminating hepatitis-induced liver failure following treatment of multiple myelomas with PAD regimen: A case report
  • Yu Li
  • 2012
  • Corpus ID: 76405228
Objective To report a case of multiple myelomas who developed fulminating hepatitis following treatment with PAD regimen… 
2010
2010
The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II…
Abstract 3052 The combination of bortezomib, doxorubicin, and dexamethasone (PAD) has shown efficacy in both relapsed/refractory… 
2009
2009
[PAD regimen for relapsed or refractory patients with multiple myeloma].
OBJECTIVE To investigate the efficacy and safety of PAD [bortezomib (PS-341), doxorubicin and dexamethasone] regimen for relapsed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)